IDEX Corporation today announced the appointment of Mark A. Buthman to the company’s Board of Directors.
“We are delighted to welcome Mark to our Board of Directors,” said IDEX Chairman and Chief Executive Officer, Andrew Silvernail. “His experience as a Chief Financial Officer of a Fortune 150 company with significant international operations and as a public company director will be a tremendous asset to IDEX. Mark is a disciplined financial leader with a track record of allocating capital in shareholder–friendly ways and his insight will be extremely valuable to our Board and management.”
Mr. Buthman retired from Kimberly–Clark Corporation in 2015, where he was Executive Vice President and Chief Financial Officer from January 2003 to April 2015. During his 33–year career at Kimberly–Clark, Mr. Buthman held a wide range of leadership roles and was part of an executive team that created more than $20 billion in shareholder value since the end of 2002. Mr. Buthman has served since 2011 as a director of West Pharmaceutical Services, Inc., a manufacturer of components and systems for the pharmaceutical, healthcare and consumer products industries.
Mr. Buthman graduated from the University of Iowa in 1981 with a degree in finance and business.
Source: IDEX
The total contract value is approximately €430 million. The project scope of work entails complete engineering services, equipment and material supply, installation and construction activities and, as an optional part of the scope, commissioning and start up.
Once it has implemented this project, Lenzing will have biological wastewater treatment plants that meet the best available techniques (BAT) quality standard at all its production sites.
The debate over the position of hydrogen in the new energy revolution has come to the fore again thanks to Japan’s hosting of the Olympic Games. But rather than showcasing how green this miracle new fuel is, it has highlighted its many problems.
